214 replies to this topic

[resveratrol_guy]

The Cancer Compass patient used sodium bicarbonate to alkalize the tumor environment. It seems from what I've read on Longecity that potassium bicarbonate might have been a better choice, for example in the context of potassium ascorbate for cancer. Also, that thread is literally 300+ pages. Can you tell us how long this gall bladder patient survived after 3BP?

 

The (not gall) bladder patient, on the other hand, may well still be alive. It's a shame that Dayspring hasn't posted any followup. They've failed to do so in every case, it seems. I suppose they're understandably afraid to publish bad news, but doing so might actually help to demonstrate the effectiveness of 3BP; no one expects perfection.

[niner]

The (not gall) bladder patient, on the other hand, may well still be alive. It's a shame that Dayspring hasn't posted any followup. They've failed to do so in every case, it seems. I suppose they're understandably afraid to publish bad news, but doing so might actually help to demonstrate the effectiveness of 3BP; no one expects perfection.

 

Or maybe they aren't posting followup because the stories don't end well.  Maybe 3BP isn't the miracle cure that they're making it out to be.  I have a bad feeling about Dayspring. 

[mag1]

Thanks a lot res_guy!

 

From what I understand one of the protocols uses sodium bicarbonate, though this might not be optimal.

 

Yet, one of the patents mentioned that potassium was specifically avoided as a buffer due to possible toxicity.

 

".. potassium has been shown to exhibit toxicity (hyperkalemia) in some human studies"

"In addition, by using a non-potassium containing buffer, e.g., a sodium phosphate buffer, potential heart and other problems related to potassium toxicity are eliminated."

Not sure whether this applies in this instance.

https://www.google.c...d=0CCMQ6AEwATgK

 

Will need to consider this further.

 

Thank you also for asking about the gall bladder patient.

I believe I actually mislabeled the patient in a post two or three back.

This patient had bile duct cancer and the clinical prognosis was desperate.

Her doctors explained that chemo would almost certainly not be helpful.

 

This patient's report has almost disappeared from the internet.

From what I can make out, a crowdfunding campaign raised quite a bit of money and she went to Dayspring for treatment.

After only about 2 weeks of treatment, she needed to be rehospitalized.

It is not clear how many or any treatments of 3-BP were given to her.

However, as I recall the crowdfunding site noted that after the treatment her markers had decreased by about 5%.

 

The patient did not survive beyond much more than a month after being rehospitalized.

 

The Cancer Compass thread has attracted quite a few of the leaders in the 3-BP community.

The pancreatic cancer patient stopped by and seemed to be doing fairly well.

There is also an invitation for the bladder cancer patient to make an appearance.

 

Anyone else interested in hearing how someone with cancer so severe that even Dayspring briefly considered

that the patient was untreatable has apparently now made a recovery?

 

This patient is tipping the balance for me.

I do not see how it can be considered reasonable anymore not to consider Dayspring if no options are forthcoming.

I do not think it is reasonable to wait until the last minute.

 

Dayspring has updated some of the patients, though I suppose there is always the tendency of the healthy patients to be

lost to followup. I would tend to think that patients who initially had good responses would be in contact with Dayspring if

there were set backs.

 

At the same time I certainly understand how we would all like more transparency.

3-BP is a nearly entirely opaque treatment.

Science is not based on anecdotes or unreferenced claims.

 

Probably a large part of the problem is that finding a sustainable business model for 3-BP is likely more of a challenge than

the actual science. Dayspring has staked out an approach that has allowed them to offer 3-BP treatment without fully disclosing

the details of their approach. Such a strategy has allowed them to protect their intellectual property even while 3-BP, the chemical,

itself might have certain patent challenges. 

 

 

 

Edited by mag1, 09 May 2016 - 04:23 AM.

[mag1]

res_guy, near the start of the thread you said that this was THE thread for 3-BP on the forum. I think you are so right.

 

After looking back on the thread, I think we hit pretty much the right tone.

Quite a few of your comments really seem spot on.

 

Considering that we live our life with time moving forward, it is somewhat impressive that even when the clock is reversed

our comments are still fairly on the mark.

 

There are a few items that I should add.

Quite a few internet rumors are swirling about 3-BP, they are probably unverifiable though it would be good to acknowledge them all the same.

 

The Cancer Compass noted that based on information from a patient's personal knowledge an underground 3-BP clinical trial apparently

was underway at PMH in Toronto (One of the largest cancer hospitals in North America.)  Not entirely sure how you could do such

an underground trial.

   

A gofundme campaign is raising money for the broad concept of 3-BP treatment.

The website is claiming that a 3-BP clinical trial is either planned or underway in Holland (?).

(click on the more link on the last update.)

 

This site is also trying to receive Health Canada approval for patients to receive 3-BP treatment under the Special Access Program (SAP).

If this were to be authorized, then one might, as the SAP is a rules based process, expect that such authorizations would apply to all cancer patients

who met certain conditions.  

 

https://www.gofundme...gbdys-utm_sourc

 

It is also of note that the impressive responses seen with several of the patients that have been treated at Dayspring

can not be attributed to selection bias. Alternative medicine has often reported on the 1 patient in a 1000 with a good response

while ignoring all those who did not fare as well. However, the Cancer Compass thread mentioned that the pancreatic patient

treated at Dayspring who had an impressive response to 3-BP was the only pancreatic patient treated to that point with 3-BP.

 

It appears that the bladder cancer who was recently reported on their site was likely also the first or nearly the first Bladder patient treated at Dayspring.

This information is from an Inspire thread that reported no bladder cancer patients had been treated at Dayspring up till August of last year.

 

The latest Bladder Cancer is truly startling. The patient report on Dayspring talked of there being discussion of obtaining a death certificate

for the patient instead of starting treatment. Their commentary then goes on to say that this patient is now expected to recover.

 

It seems as though there was no selection bias for either the pancreatic or bladder patients.

This makes these two patient reports on Dayspring all the more impressive.

 

 

Edited by mag1, 10 May 2016 - 02:10 AM.

[mag1]

There has been a massive development in 3-Bromopyruvate.

 

A clinic in Germany is now under investigation for at least 3 deaths possibly related to 3-Bromopyruvate treatment.

The cancer compass thread was aware of a new management arrangement at this Bracht clinic for the last several months.

 

http://www.dpa-inter...60806-99-954398

http://edzardernst.c...-caused-by-3bp/

http://www.spiegel.d...-a-1106218.html

 

Much of the reporting to date has been extremely misinformed.

 

The patients in this incident died days after treatment.

Typically with 3-BP there is no existing drug even hours after a treatment.

It seems unlikely that 3-BP was the actual cause of any of these fatalities.

The batch of drug used might have been chemically impure or contaminated with an infection.  

 

Considering the scope of this tragedy, it should be expected that a thorough and exhaustive investigation will occur.  

Those in the 3-Bromopyruvate community greatly welcome such an opportunity to explore the evidence surrounding 3-Bromopyruvate.

 

This evidence has been accumulating now over the last two decades.

The upcoming inquiry could be a forum for high level scientific discourse on 3-BP, a very important emerging cancer therapy. 

A recent review article gave a very good up to date summary of the 3-BP knowledge base.

http://www.ncbi.nlm....pubmed/27457582

 

For starters, the extremely impressive response to 3-BP of this patient with terminal liver cancer.

http://www.ncbi.nlm..../?term=22328020

 

The metabolic cure that occurred in this melanoma patient with overwhelmingly severe metastatic illness.

http://www.ncbi.nlm....pubmed/24636230

 

Not to mention unpublished though reported patient reports including at Johns Hopkins University, Columbia, Toronto,

Arizona among others.

 

 

 

 

 

 

 

 

 

Edited by mag1, 07 August 2016 - 04:57 AM.